Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), announced today the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The appointment consolidates the previously separate COO roles for Drug Substances and Drug Products into a single position, aligning with Siegfried's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Eduardo Montanha brings over 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he managed an integrated global network of approximately 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership roles at Takeda, Sandoz, Hexal, and Hoechst/Aventis, focusing on technical operations, quality, supply chain, and large-scale manufacturing.
In his new role, Montanha will focus on strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. Siegfried CEO Marcel Imwinkelried stated, "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. His international experience spans Europe and Latin America, which will be critical as Siegfried continues to expand its global footprint. The company operates 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China, and reported sales of CHF 1,327.8 million in 2025 with over 3,800 employees.
This leadership change underscores Siegfried's commitment to providing integrated services from drug substances to drug products, a move expected to enhance customer value and operational agility. For more details, refer to the original press release at NewMediaWire or Siegfried's official site at www.siegfried.ch.
